Exciting Partnership for Lung Cancer Research
The Lung Cancer Research Foundation (LCRF) is thrilled to announce its collaboration with the Israel Cancer Research Fund (ICRF). This partnership aims to advance innovative treatments for lung cancer, particularly targeting KRAS mutations, which are prevalent in many patients. Led by Joel Yisraeli, PhD, at the Hebrew University of Jerusalem, this initiative focuses on understanding and combating the complexities of lung adenocarcinoma.
The ICRF-LCRF Project Grant
This collaborative effort is supported by the ICRF-LCRF Project Grant, which allocates $180,000 over three years to fund vital research. The project, titled "Treating Lung and Colorectal Carcinomas by Targeting IGFBP1," will explore the effects of a new inhibitor known as IGF2BP1, discovered by Professor Yisraeli and his team.
Importance of IGF2BP1 in Cancer
IGF2BP1, a protein that typically operates during developmental stages, becomes reactivated in various cancers, particularly lung adenocarcinoma. Patients exhibiting elevated IGF2BP1 levels along with a KRAS mutation face starkly reduced survival rates. Research indicates that in mice, the activity of IGF2BP1 in tandem with KRAS mutations accelerates tumor growth and metastasis. Therefore, inhibiting IGF2BP1 may offer significant therapeutic potential.
Innovative Treatments on the Horizon
Professor Yisraeli’s laboratory has made strides in refining a molecule called AVJ16, which effectively inhibits IGF2BP1's binding to KRAS and other RNAs involved in cancer progression. In preclinical studies using mouse models, AVJ16 has shown promise in halting the growth of cancer cells. This collaboration seeks to evaluate the efficacy of AVJ16 in genetically modified mouse models designed to simulate lung cancer, ultimately aiming to develop new therapies that specifically target IGF2BP1.
Targeting KRAS Mutations
KRAS mutations represent a significant challenge in treating non-small cell lung cancer, comprising about 25% of all lung cancer cases. These mutations disrupt normal cell growth signaling pathways, leading to unchecked cell proliferation. Although targeted therapies for certain KRAS mutations exist, they are not universally effective. Thus, ongoing research into additional therapeutic options is crucial in the fight against these aggressive cancers.
Building on Previous Research
Professor Yisraeli has a rich history of research funded by ICRF, which has supported his innovative studies from the inception of his laboratory at the Hebrew University. This prior funding has been instrumental in paving the way for his current endeavor in lung cancer research, ultimately contributing to a broader understanding of cancer biology.
Antoinette Wozniak, MD, Chief Scientific Officer at LCRF, expressed enthusiasm for the collaboration, highlighting the importance of exploring new treatment avenues for notoriously hard-to-treat cancers. Arnold Baskies, MD, Chair of the Board of Trustees at ICRF, echoed this sentiment by emphasizing the significance of a partnership that enhances their efforts to improve lung cancer outcomes through cutting-edge research.
About the Organizations
The Lung Cancer Research Foundation is dedicated to funding transformative research projects aimed at improving lung cancer survival and quality of life. Since its inception, LCRF has allocated nearly $48 million in funding for lung cancer research initiatives.
On the other hand, the Israel Cancer Research Fund stands as the leading nonprofit supporter of cancer research in Israel, with a notable track record of funding significant scientific endeavors across various institutions. Their collective goal remains clear: to eliminate the suffering caused by cancer through groundbreaking research.
Frequently Asked Questions
What is the focus of the LCRF and ICRF partnership?
The partnership focuses on innovative research targeting KRAS mutations in lung cancer, aiming to develop new therapeutic options.
Who is leading the research project?
The project is led by Professor Joel Yisraeli from the Hebrew University of Jerusalem.
What is the significance of IGF2BP1 in lung cancer?
IGF2BP1 is a protein linked to higher tumor growth rates in lung cancers, making it a critical target for therapy.
How much funding has been allocated for this research?
The ICRF-LCRF Project Grant provides $180,000 over three years for this research initiative.
What is the ultimate goal of the research?
The ultimate goal is to create new therapies that specifically inhibit IGF2BP1 and improve outcomes for lung cancer patients.
